Recently by John T. Delacourt
Health Care Policy Reform Agenda Puts "Reverse Payment" Agreements Between Branded And Generic Drug Makers In The Spotlight: Proposals To Ban Payments Gaining Momentum
This article addresses recent and upcoming developments regarding "reverse payment" pharmaceutical settlements, including: an unresolved circuit split, harmonization of Department of Justice ("DOJ") and Federal Trade Commission ("FTC") antitrust approaches, and a flurry of pending legislation....
Read MoreThe Leegin Case: Antitrust Prohibition On Minimum Resale Price Maintenance Subject To The Rule Of Reason
Editor: Mr. Delacourt, would you tell our readers something about your background and professional experience? Delacourt: I am currently in private practice with the law firm of Kelley Drye & Warren LLP, where I specialize in antitrust law. Prior to joining the firm, I served as Chief...
Read More